FDA Approves Abbott Laboratories’ Insulin-monitoring AppNovember 21st, 2018
QBC Capillary Centrifuge - An Ultra-compact Device for Rapid Hematology TestingNovember 19th, 2018
MEDICA 2018 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
ChicagoBooth No.: 3849
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
The West Nile IgG Test is an ELISA assay system for the detection of antibodies in human serum to WNV derived recombinant antigen (WNRA) (1-3). This test is to aid in the determination of human exposure to the West Nile Virus.
The West Nile IgG ELISA consists of one enzymatically amplified "two-step" sandwich-type immunoassays. In this assay, the microtitration wells are incubated with standards, controls or unknown serum samples. The serum samples may be directly mixed with sample dilution buffer added in the wells (also see note below). After washing, the wells are treated with an antibody specific for human IgG and labeled with the enzyme horseradish peroxidase (HRP).
After a second incubation and washing step, the wells are incubated with the tetramethylbenzidine (TMB) substrate. Note: Depending on the strength of antibody response, sera can be diluted in a diluent provided in the kit. An acidic stopping solution is then added and the degree of enzymatic turnover of the substrate is determined by absorbance measurement at 450 nanometers. Above a certain threshold, the ratio of the absorbances of the WNRA and the control wells accurately determines whether antibodies to WNV are present. A set of positive and negative samples is provided as internal controls in order to monitor the integrity of the kit components.